Company intelligence / Profile preview

Nemdx

Boston, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Nemdx is developing a proprietary diagnostic tools platform based on synthetic short RNA binders that directly bind proteins and peptides to enable ultra‑sensitive, highly specific detection of disease-related protein activity and modifications; its first applications are in blood-based biomarker panels for ALS and other neurodegenerative diseases, with work currently at research and preclinical validation stage.[1][3][6]

Therapeutic areas: Neurology
Modalities: RNA therapySynthetic oligonucleotideDevice
Industry: Protein Biomarker Diagnostics

Partnerships

Massachusetts General Hospital (Sean M. Healey & AMG Center for ALS)International Centre for Genetic Engineering and BiotechnologyALS Finding a Cure (research funding partner)

Beyond the preview

Go deeper on Nemdx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nemdx.

Explore the full profile